Inj ontruzant 10 mg
Products billed under this code include Ontruzant.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Ontruzant.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Ontruzant | Organon LLC | 78206-0147-01 | 15 | $491.865 |
| Ontruzant | Organon LLC | 78206-0148-01 | 42 | $1,377.222 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $32.791 | +$11.802 | 10 MG | Inj ontruzant 10 mg | v1, posted September 17, 2026 |
| 3Q26 | $20.989 | −$8.819 | 10 MG | Inj ontruzant 10 mg | v1, posted September 15, 2026 |
| 2Q26 | $29.808 | +$2.536 | 10 MG | Inj ontruzant 10 mg | v1, posted September 15, 2026 |
| 1Q26 | $27.272 | +$8.271 | 10 MG | Inj ontruzant 10 mg | v1, posted September 15, 2026 |
| 4Q25 | $19.001 | −$2.984 | 10 MG | Inj ontruzant 10 mg | v1, posted September 8, 2026 |
| 3Q25 | $21.985 | −$6.755 | 10 MG | Inj ontruzant 10 mg | v1, posted March 10, 2026 |
| 2Q25 | $28.74 | +$2.371 | 10 MG | Inj ontruzant 10 mg | v1, posted March 10, 2026 |
| 1Q25 | $26.369 | −$7.796 | 10 MG | Inj ontruzant 10 mg | v1, posted December 19, 2025 |
| 4Q24 | $34.165 | +$1.71 | 10 MG | Inj ontruzant 10 mg | v1, posted June 11, 2025 |
| 3Q24 | $32.455 | −$1.602 | 10 MG | Inj ontruzant 10 mg | v1, posted June 11, 2025 |
| 2Q24 | $34.057 | −$4.879 | 10 MG | Inj ontruzant 10 mg | v1, posted March 11, 2025 |
| 1Q24 | $38.936 | −$2.715 | 10 MG | Inj ontruzant 10 mg | v1, posted December 19, 2024 |
| 4Q23 | $41.651 | −$5.276 | 10 MG | Inj ontruzant 10 mg | v1, posted October 10, 2024 |
| 3Q23 | $46.927 | −$2.926 | 10 MG | Inj ontruzant 10 mg | v1, posted June 5, 2024 |
| 2Q23 | $49.853 | −$8.49 | 10 MG | Inj ontruzant 10 mg | v1, posted February 23, 2024 |
| 1Q23 | $58.343 | −$4.777 | 10 MG | Inj ontruzant 10 mg | v1, posted December 6, 2023 |
| 4Q22 | $63.12 | −$5.377 | 10 MG | Inj ontruzant 10 mg | v1, posted June 22, 2023 |
| 3Q22 | $68.497 | −$8.389 | 10 MG | Inj ontruzant 10 mg | v1, posted June 9, 2023 |
| 2Q22 | $76.886 | +$15.781 | 10 MG | Inj ontruzant 10 mg | v1, posted December 14, 2022 |
| 1Q22 | $61.105 | −$5.445 | 10 MG | Inj ontruzant 10 mg | v1, posted June 8, 2022 |
| 4Q21 | $66.55 | −$5.525 | 10 MG | Inj ontruzant 10 mg | v1, posted June 2, 2022 |
| 3Q21 | $72.075 | −$8.089 | 10 MG | Inj ontruzant 10 mg | v1, posted June 2, 2022 |
| 2Q21 | $80.164 | −$8.002 | 10 MG | Inj ontruzant 10 mg | v1, posted March 1, 2022 |
| 1Q21 | $88.166 | – | 10 MG | Inj ontruzant 10 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.